Sam Costello (The Queen Elizabeth Hospital in Adelaide) presented recent evidences about FMT and IBDs.
COVID-19 alters the local immunity of the lung in ways that weaken the body’s antimicrobial defense and facilitate the development of secondary infections.
The findings of a recent study suggest that phages can be used to treat IBD and other diseases associated with gut microbes.
RBX2660 is an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrence of C. difficile infection after antibiotic treatment
The Italian-based leader in the European nutraceutical CDMO market announces the acquisition of Nutraskills, a French company specialized in the research and development, production, and packaging of food supplements for…
Ghaith Bakdash described how Microbiotica discovered a specific microbiome signature in patients responder to immune-oncology drugs such as anti-PD1 / PDL1 and developed a new bacterial consortium.
The findings of a recent study suggest that engineered native gut bacteria could be employed to help treat certain diseases such as diabetes.
A recent study suggests that the microbiome changes in response to human consumption of non-nutritive sweetener may induce glycemic changes in consumers in a personalized manner.
Sarah Lebeer (Research professor, University of Antwerp) described how she and her colleagues developed a new probiotic topic formulation to treat Acne.
The intestinal microflora of infants should contain a high proportion of Bifidobacteria during their first year of life to be well preserved and balanced
